-transparent.png){kind=logo}
The presence as well as the pharmacological, molecular, and functional properties of pituitary adenylate cyclase-activating peptide (PACAP) receptors have been analyzed in human liver membranes compared in parallel with vasoactive intestinal peptide (VIP) receptors. [125I]PACAP-27 bound to two classes of receptors with high [dissociation constant (Kd) = 0.47 nmol/L] and low (Kd = 8.0 nmol/L) affinities that represented about 34% and 66% of total binding sites, respectively. The pharmacological profile of [125I]VIP and [125I]PACAP-27 binding to membranes supported the coexistence with VIP receptors of specific receptors for PACAP with a mol wt equal to 67.7K. When [125I]PACAP-27 was used, the order of potency of various related peptides for competition of tracer binding was PACAP-27 greater than PACAP-38 greater than VIP. Both PACAP-27 and VIP stimulated adenylate cyclase activity with similar efficacy, although PACAP-27 showed a potency (half-maximal efficient concentration or EC50 = 0.5 nmol/L) greater than that of VIP (EC50 = 4.1 nmol/L). When the two peptides were present simultaneously in the incubation medium, no additive effect on the stimulation of adenylate cyclase activity was observed, which suggests a unique receptor coupled to this enzyme.
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
November 1993,
The Journal of clinical endocrinology and metabolism,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
April 1996,
Journal of cellular physiology,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
October 1992,
Trends in endocrinology and metabolism: TEM,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
July 1996,
Endocrinology,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
April 2018,
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
December 2001,
Peptides,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
January 2020,
General and comparative endocrinology,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
June 2005,
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
February 2016,
Current opinion in endocrinology, diabetes, and obesity,
L G Guijarro, and
N Rodriguez-Henche, and
E García-López, and
F Noguerales, and
M A Dapena, and
M G Juarranz, and
J C Prieto
December 1998,
Annals of the New York Academy of Sciences,
